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Background
Rheumatic diseases (RDs) can be defined as syste-
mic diseases affecting the connective tissue (inclu-
ding joint components) and other medical disor-
ders of the musculoskeletal system. Clinically, they
are characterized by pain and/or stiffness and di-
sability, and in some cases, inflammation. They
may or may not be accompanied by involvement
of other organs and systems. RDs are among the
most common diseases managed at the primary
health care level, as well as the leading cause of di-
sability in the developed world, and consume a lar-
ge amount of health and social resources1-3.
Prevalence of RDs needs to be assigned to spe-
cific populations, as different populations with dif-
ferent genetic and environmental backgrounds
show different rates. Furthermore, in the context of
increasing treatment costs, economic constraints
and managed care, specific local data on the pre-
valence and local major determinants of different
diseases might help healthcare systems develop
specific plans for the care of a given disease.  At a
national level, knowledge of the most important
RDs and their consequences is essential for plan-
ning the needs of healthcare professionals, infras-
tructures, and resources. In Portugal, the prevalen-
ce of RDs is ill-defined. A nationwide epidemiolo-
gical study is the only way to fulfill this need, and it
is also a specific objective of the National Program
Against Rheumatic Diseases (“Programa Nacional
Contra as Doenças Reumáticas”). Furthermore, the
knowledge of the burden of RDs will raise public
awareness on their importance and impact in our
society.
Well-designed and consistent RDs epidemiolo-
gical studies have not been performed in Portugal,
as opposed to what has happened in several other
European countries, such as Spain and Greece4, 5.
No population-based studies have been done on
the prevalence of any of the rheumatic symptoms
or RDs in the Portuguese population. Furthermo-
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sing homes, military barracks, or prisons, and resi-
dents unable to speak Portuguese or with a com-
plete inability to answer the questionnaire, either
directly or through a person living with him/her.
The sample will be representative of the Portugue-
se population. Locations will be selected as the pri-
mary unit of sampling and, according to the CEN-
SUS 2001. Excluding the islands, there are 27,960 lo-
calities in Portugal), with a total population of
7,719,986 subjects aged 18 years or older7. The sam-
ple size will be stratified for region and dimension
of the location (< 2,000; 2,000-9,999; 10,000-19,999;
20,000-99,999; and 100,000 inhabitants). The num-
ber of questionnaires in each stratum will be pro-
portional to the real distribution of the population.
Because there is no reliable list of households in
Portugal, a random selection of points in the map
of each location will be performed. Addresses will
be selected, and afterwards the “random-walks”
will start. Interviewers will register each selected
address and, if someone is at home, they will col-
lect information on age and gender of the different
people living in that address, and will give informa-
tion about the study. After validation of the selec-
ted address and inhabitants, the interviews will be
scheduled. In order to assure the successful data
collection, up to three visits to each address (one
during the weekend) will be made. Interviewers will
collect 20% additional addresses in each point to
compensate for possible refusals to participate. At
each address, the person whose birthday is closest
to the day of the visit (aged 18 years or older) will
be selected for the interview and, if available, will
be immediately asked to answer the questionnaire. 
Primary objective and case definition
The primary objective will be the prevalence of the
following rheumatic diseases: osteoarthritis (knee,
hip and hand), low back pain (LBP), osteoporotic
fractures (OPF), periarticular RD (PRD), fibromyal-
gia (FM), rheumatoid arthritis (RA), spondylo-
arthritis (SpA, as well as its major subtype, ankylo-
sing spondylitis – AS), systemic lupus erythemato-
sus (SLE), polymyalgia rheumatica (PMR), and gout
(GO). A major risk of fragility fracture within 10 ye-
ars will also be calculated.
Case definition: The diagnosis of RD, either active
or in remission, will be based on the American Col-
lege of Rheumatology (ACR, formerly the Ameri-
can Rheumatism Association) criteria (for RA, SLE,
GO, OA, and FM)8-17 or other internationally used
criteria (for PMR, SpA and AS)18,19. 
re, the impact of RDs on quality of life and on func-
tion has never been assessed at a population level,
despite the fact that quality of life is the most im-
portant indicator of the burden of this group of di-
seases6. Thus, it is crucial to assess the impact of
rheumatic diseases on the general population in
terms of their prevalence, effect on quality of life,
and function. 
An epidemiologic study of RDs has long been
necessary in Portugal, but it has been repeatedly
postponed due to financial constraints. Herein we
are presenting a project where we hope to have fi-
nally met all the minimum requirements to deve-
lop and undertake an epidemiological study deter-
minant for the future of Portuguese rheumatology
and of patients with RDs.
Objectives
Primary Objective
Estimate the prevalence of the different RDs in Por-
tugal;
Secondary Objectives:
1. Estimate the prevalence of the different RDs ac-
cording to socio-demographic characteristics;
2. Identify socio-demographic and clinical varia-
bles associated with the diagnosis of some RDs;
3. Estimate the frequency of previously undiagno-
sed RDs;
4. Determine the impact of RDs on quality of life
and on functional and work capacity;
5. Investigate the access to healthcare of patients
with RD;
6. Compare the burden of RDs in Portugal with the
reality from other countries;
7. Define two cohorts, one with and another wi-
thout RD, to be followed prospectively.
Methodology
Study design
A cross-sectional study will be performed.
Study population
The study population will be composed by adults
(≥ 18 years old) who are non-institutionalized and
living in private households in Portugal, from the
Mainland and Islands (Madeira and Açores). Ex-
clusion criteria will be: residents in hospitals, nur-
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Knee osteoarthritis will follow the ACR criteria15:
the patient should have knee pain plus at least 3 of
the following 6 clinical findings: a) age > 50 years;
b) morning stiffness < 30 minutes of duration; c)
crepitus on active motion; d) tenderness of the
bony margins of the joint; e) bony enlargement no-
ted on examination; e) a lack of palpable warmth
of the synovium.
Hip osteoarthritis will be defined, according to
the ACR criteria13, as hip pain plus one of the fol-
lowing: a) hip internal rotation <15º and erythro-
cyte sedimentation rate (ESR) ≤45mm/hour (if ESR
not available, substitute hip flexion ≤115º); b) hip
internal rotation ≥15º and pain on hip internal ro-
tation and morning stiffness of the hip ≤ 60 minu-
tes and age > 50 years.
Hand osteoarthritis will be defined according to
the ACR criteria14: the patient should fulfill the fol-
lowing 3 criteria: a) hand pain, aching, or stiffness;
b) hard tissue enlargement of 2 or more of 10 selec-
ted joints; c) fewer than 3 swollen metacarpopha-
langeal joints; the fourth criteria corresponds to
the presence of one of the following two: d) hard tis-
sue enlargement of 2 or more DIP joints, or e) de-
formity of 2 or more of 10 selected joints.
LBP will be defined by self-report. The inter-
viewers will be instructed to indicate what is under-
stood by low back, more specifically the back area
between the lower limits of the chest and the glu-
teal folds,  and then to ask about pain in that area.
In case of positive LBP, red flags will be searched, in
order to detect a cause of specific LBP, namely in-
fection, inflammatory disease and cancer22. The po-
int prevalence of LBP will be estimated and, for this
purpose, LBP on the day of the interview will be
considered. Prevalence of LBP in the previous 6
months will also be estimated and further specifi-
ed into acute LBP (less than 6 weeks), subacute LBP
(between 6 weeks and 3 months) and chronic LBP
(more than 3 months). Disabling acute LBP will be
defined as a LBP preventing the patient from per-
forming the activities of daily living, and with a sco-
re of at least eight, on a 0-10 pain visual analogue
scale.
Densitometric osteoporosis will be underestima-
ted due to the impossibility of screening all parti-
cipants with dual energy x-ray absorptiometry
(DXA). For the current study, a definition of OPF will
be used and considered as positive in the case of
history of a low impact bone fracture or of x-ray
documenting vertebral fractures in post-menopau-
sal women or men above 50 years old. The risk of a
major fracture will be defined as a Fracture Risk As-
sessment Tool (FRAX – http://www.shef.ac.uk/
FRAX/)23 score of >10% (with or without DXA). Fur-
thermore, some participants (the ones that will be
evaluated by a rheumatologist, as explained below)
will be submitted to a wrist DXA. The criteria to
perform DXA will be in accordance with the guide-
lines from the Portuguese Society for Rheumato-
logy (PSR)24. Osteoporosis will be defined accor-
ding to the definition from the World Health Orga-
nization: bone density 2.5 standard deviations be-
low the average of the healthy adult reference range
(T score < -2.5)25.
PRDs will be defined as a regional pain syndro-
me affecting muscles, tendons, bursas or periarti-
cular soft tissues, with or without evidence of joint
or bone involvement. The following PRDs will be
specifically searched:  tenosynovitis, adhesive cap-
sulitis of the shoulder, enthesopathy, bursitis, pal-
mar or plantar fasciitis, and carpal or tarsal tunnel
syndrome present at the time of the interview. The-
se will be diagnosed based on the main clinical ma-
nifestations and, in some instances, on exams (eg:
radiographs, ultrasounds) findings. 
For fibromyalgia, two classification criteria will
be used, namely the 1990 ACR criteria16, as well as
the new ones, recently published17. According to
the 1990 ACR criteria16, fibromyalgia is defined as:
a) history of widespread pain (present in both sides
of the body, above and below the waist) for at least
3 months; b) pain in 11 of 18 tender point sites on
digital palpation. According to the 2010 ACR crite-
ria17, fibromyalgia is defined as: a) widespread pain
index (WPI) ≥ 7 and symptom severity (SS) scale
score ≥ 5 or WPI 3-6 and SS scale score ≥ 9; WPI is
the number of areas in which the patient has had
pain over the last week and can vary between 0 and
19; SS scale score is the sum of severity of the 3
symptoms – fatigue, waking unrefreshed, and cog-
nitive symptoms, plus the extent of somatic symp-
toms in general, and the final score is between 0 and
12; b) symptoms have been present at a similar le-
vel for at least 3 months; c) the patient does not
have a disorder that would otherwise explain the
pain. 
Similarly, new classification criteria for RA have
been recently developed9. Consequently, they will
also be taken into account and the prevalence of RA
will be reported according to both classification cri-
teria, the 1987 ARA revised criteria for the classifi-
cation of RA8 and the new ones. RA will be diagno-
sed according to the 1987 ARA criteria8 if 4 or more
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of the following are present: a) morning stiffness
longer than 1h present during at least 6 weeks; b)
arthritis of 3 or more joint areas (≥ 6 weeks); c)
arthritis of hand joints (≥ 6 weeks); d) symmetric
arthritis (≥ 6 weeks); e) rheumatoid nodules; f ) se-
rum rheumatoid factor; g) typical radiographic
changes of RA on hand radiographs. The new clas-
sification criteria consist of a scoring system, accor-
ding to which an individual with a score ≥6 (out of
10) is considered to have RA9. Furthermore, with the
adaptation for populational studies, the following
situations will also be considered as RA: a confir-
med diagnosis of RA, deformities clearly compati-
ble with RA or RA criteria in the past26. 
SpA will be defined according to the Assessment
of SpondyloArthritis International Society (ASAS)
criteria for axial SpA19 and also for peripheral SpA20.
A diagnosis of axial SpA will be established if a pa-
tient with back pain ≥ 3 months and age at onset
≤45 years has sacroiliitis in imaging (magnetic re-
sonance imaging or conventional radiograph) plus
one or more SpA features or HLA-B27 positive plus
2 or more other SpA features. SpA features can be
any of the following: inflammatory back pain,
arthritis, enthesitis, uveitis, dactylitis, psoriasis,
Crohn’s disease/ulcerative colitis, good response 
to non-steroidal anti-inflammatory drugs, family
history for SpA, HLA-B27, elevated C-reactive pro-
tein. Patients with SpA fulfilling the modified New
York criteria will be further specified as having
Ankylosing Spondylitis (AS)21. Peripheral SpA will be
established in the presence of arthritis or enthesi-
tis or dactylitis plus a) one of the following SpA fea-
tures: psoriasis, inflammatory bowel disease, pre-
ceding infection, HLA-B27, uveitis, and sacroiliitis
on imaging; or b) two of the remaining SpA featu-
res: arthritis, enthesistis, dactylitis, inflammatory
back pain in the past, and positive family history for
SpA20.
SLE will be defined according to the 1997 revi-
sed ACR criteria11 and at least 4 of the following
must be present: a) malar rash; b) discoid rash; c)
photosensitivity; d) oral ulcers; e) non-erosive
arthritis; f ) pleuritis or pericarditis; g) renal disor-
der; h) neurologic disorder; i) hematologic disorder;
j) immunologic disorder; k) positive antinuclear
antibody. 
PMR will be diagnosed, according to the criteria
published by Bird et al.18, in the presence of 3 of the
following: a) bilateral shoulder pain or stiffness; b)
onset of illness of less than 2 weeks’ duration; c) ini-
tial ESR greater than 40mm/h; d) duration of mor-
ning stiffness exceeding 1 hour; e) age 65 years or
more; f ) depression and/or weight loss; g) bilateral
tenderness in the upper arms.
Gout will be defined according to the ACR crite-
ria12 and will be established in the presence of 6 of
the following 11 criteria: a) more than one attack of
acute arthritis; b) maximum inflammation develo-
ped within 1 day; c) oligoarthritis attack; d) redness
observed over joints; e) first metatarsophalangeal
joint painful or swollen; f ) unilateral first metatar-
sophalangeal joint attack; g) unilateral tarsal joint
attack; h) tophus (proven or suspected); i) hyperu-
ricemia; j) asymmetric swelling within a joint on 
x-ray; k) complete termination of an attack. 
Secondary objectives
Secondary aims will be the evaluation of quality of
life, functional and work capacity and access to he-
alth care, more specifically the comparison betwe-
en participants with and without an RD.
Quality of life will be evaluated by the Short
Form-36 (SF-36), which yields a continuous result
in two scales, physical and mental, each ranging
from 0 (worst state) to 100 (best state). This instru-
ment has been validated for the Portuguese popu-
lation27, 28.
Functional capacity will be assessed by the
Health Assessment Questionnaire (HAQ)29, which
measures difficulty in performing the activities of
daily living, and ranges from 0 (no limitation) to 3
(highest limitation).
Work disability will be evaluated by absenteeism,
presenteeism, early retirement, and unemploy-
ment due to work disability.
Access to health care will be evaluated by Rheu-
matology consultation (ever, frequent rheumato-
logy consultations - >1 consultation/year, number
of consultations in the last year) and exemption
from user fees due to RD. 
Study Procedures
Trained interviewers will visit the target populati-
on at their homes door-to-door. This screening in-
volves an interview for each participant and will be
based on a standardized questionnaire. Its purpo-
se is to obtain information on 1) socio-demo-
graphic characteristics, 2) medical history, 3) iden-
tification of subjects with a potential RD, and 4) as-
sessment of physical function (HAQ), quality of life
(SF-36), work ability and access to health care. Me-
dical history will include questions about previous
diagnosis of RD, intake of a list of antirheumatic
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drugs, including non-steroidal anti-inflammatory
drugs (NSAIDs) for more than one month in total,
and the need for medical appointments due to
musculoskeletal symptoms in the previous year.
In the presence of a diagnosis of RD, questions will
address the examinations performed to reach that
diagnosis, as well as the name of the medical spe-
ciality that established the diagnosis.
The screening questionnaire will be developed
in several steps:
1. Questionnaire development: preparation of the
questionnaire by a team composed by rheuma-
tologists and epidemiologists;
2. Validation study: to assess the properties of the
screening questionnaire (mainly sensitivity and
specificity) a validation study will be carried out
prior to the start of the study, involving partici-
pants with and without an RD. The recruitment
of these cases and controls will be hospital-ba-
sed, from outpatient clinics;
3. Potential refinement of the questionnaire, if ne-
cessary after the validation study;
4. Preparation of the data collection forms to be
applied through Computer Assisted Personal In-
terviewing methods;
5. Pilot study: a pilot study will be carried out to de-
tect possible errors in the design of the data col-
lection forms, to assess feasibility of the recruit-
ment, to estimate the interviews’ duration, and
to estimate the percentage of non-responders
and the causes of non-collaboration;
6. Application of the final questionnaire.
Participants identified by this screening ques-
tionnaire as potentially having an RD, as well as
some of the patients considered as not having an
RD (20-30% depending on the accuracy of the
questionnaires, as determined in interim analy-
ses), will be evaluated by a rheumatologist accor-
ding to a structured protocol. Participants will be
evaluated in a diagnostic van, fully equipped for
the purpose. The evaluation by a rheumatologist
will include a medical history and physical exami-
nation and will be as closest as possible in time to
the screening questionnaire. Available and appro-
priate laboratory test results or imaging findings
will be evaluated during the diagnostic procedure.
During the evaluation, blood will be drawn and
kept frozen in a biobank for future research, with
the patient consent. As explained before, wrist DXA
will be performed to the participants evaluated by
a rheumatologist and with a clinical indication for
a DXA, as recommended by the PSR24. In cases
where further laboratory investigation or radio-
graphs are necessary, they will be performed as
soon as possible (most of them can already take
place inside the diagnostic van, such as conventi-
onal radiographs and blood draw for laboratory
analysis). Afterwards, participants’ data will be re-
evaluated by a rheumatologist to reach a definite
diagnosis. If necessary, the participant will be re-
evaluated by a rheumatologist. Cases that pose di-
agnostic doubts will be discussed among a scien-
tific committee composed by 3 rheumatologists
and the principal investigator. Patients with an
identified RD, not being followed by a rheumato-
logist but with clinical indication for will be refer-
red to a rheumatology appointment in their refer-
ral hospital. 
Non-responders will also be randomly analyzed,
by means of comparison of socio-demographic
characteristics, as well as clinical aspects, if avai-
lable. Therefore, non-responders will be asked to
answer a basic questionnaire designed specifically
for this purpose. Reasons for non-participation will
also be registered.
Prior to the start of the study, all participating in-
terviewers and rheumatologists will be trained in
order to standardize procedures. This training will
cover the study protocol, how to conduct the inter-
view, assessment of musculoskeletal symptoms,
and standardizing the use of the RDs classificati-
on criteria. The field work will be only undertaken
by interviewers with adequate skills to assure the
quality of the data collection. Therefore, inter-
viewers not achieving a reasonable level of knowl-
edge after the training will be excluded from the
process. Data collection forms will be further mo-
nitored centrally to check for missing data or in-
consistencies, including potential participant te-
lephone contact to confirm the answers. 
At the end of the study, two cohorts will be de-
fined for prospective follow-up, one composed by
participants with an RD and another by partici-
pants without an RD. The aim of creating these co-
horts is to investigate the evolution and outcomes
of the RDs, as well as the potential appearance of
an RD in the non-RD cohort.
Statistical Considerations
The prevalence of the different RDs will be estima-
ted with 95% confidence intervals adjusted for the
design of the study and standardized for age and
gender, according to the total adult population of
the studied areas. Comparison of demographic
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and clinical characteristics between groups (eg
with and without RD) will be undertaken using t
tests for continuous normally distributed variables
or Wilcoxon for continuous non-normally distribu-
ted variables. Chi-squared tests will be used for ca-
tegorical variables, and Fisher’s Exact test will be
used for categorical variables within smaller sam-
ple sizes. Comparison between more than two
groups will be performed through one-way analy-
sis of variance (ANOVA) for continuous variables
and chi-squared test for categorical variables. Fac-
tors significantly associated with any disease group
will be included in a logistic regression model for
further analysis. The effect of specific conditions
on quality of life and function will be assessed by
linear regression, univariably and then multivari-
ably, controlling for potential confounders and also
analyzing potential effect modification. A proba-
bility of p < 0.05 will be considered significant. All
data will be analyzed with SPSS v 17.0.
Sample Size Calculation
Sample size calculation was based on the prevalen-
ce of RA, which is expected to be between 0.5 and
1%30. Assuming a 95% confidence interval, a 0.25%
margin of error, a total population of 8,500,000
adults in Portugal, and increasing the sample size
by 50% to account for the design effect and recruit-
ment failures, a total of 9,000 participants will be
required.
Ethical considerations
Confidentiality will be safeguarded by the non-
existence of identifiers on the database. Contacts
will only be kept for logistical reasons, in order to
reach participants for posterior observation by a
rheumatologist. All participants will sign an infor-
med consent. Blood from the participants evalua-
ted by rheumatologists will be drawn and kept fro-
zen in a biobank for future research, as long as the
patient gives his/her consent.
This project will be submitted to the National
Ethics Committee from the Portuguese College of
Physicians (Ordem dos Médicos), and also to the
Comissão Nacional de Protecção de Dados
(CNPD), the Portuguese data protection authority
(in accordance with the Portuguese law number
67/98, October 26th regarding protection of perso-
nal data). The study will be conducted in accordan-
ce with the applicable laws and regulations inclu-
ding, but not limited to, the Guideline for Good
Clinical Practice (GCP) and the ethical principles
stated in the Declaration of Helsinki (amended in
Edinburgh).  
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